HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gallo, I. Articles by Duran, C. M. Search for Related Content PubMed PubMed Citation Articles by Gallo, I. Articles by Duran, C. M.

The Journal of Thoracic and Cardiovascular Surgery, Vol 86, 897-902, Copyright © 1983 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Five- to eight-year follow-up of patients with the Hancock cardiac bioprosthesis

I Gallo, B Ruiz and CM Duran

All patients undergoing a heart valve replacement with a glutaraldehyde- preserved Hancock xenograft from June, 1974, through June, 1977, were reviewed. This analysis included 403 patients: 202 having mitral valve replacement (MVR), 131 having aortic valve replacement (AVR), and 70 having mitral and aortic valve replacement (M/AVR). The hospital mortality was 9.9% (40/403): 10.8% (22/202) for MVR, 4.5% (6/131) for AVR, and 17.1% (12/70) for M/AVR. Of 363 patients discharged from the hospital, six were lost to follow-up at 24 and 37 months and they are excluded from the figures. There were 41 late deaths, which represents an incidence of 1.47% per patient-year for MVR (16/177), 1.95% per patient-year for AVR (14/122), and 3.35% per patient-year for the M/AVR (11/58). There were 37 thromboembolic events in 32 patients. This represents a linearized incidence of 1.93%, 0.97%, and 2.74% per patient-year for MVR, AVR, and M/AVR, respectively. None of the accidents was fatal, and four of the 32 patients were on a regimen of controlled anticoagulation at the time of embolism. Primary tissue failure was observed in 34 patients (231 MVR, eight AVR, and five MAVR). The probability of being free from primary tissue failure at 8 years is 85.3% +/- 3.7% for MVR, 85% +/- 11.6% for AVR, and 81% +/- 8.9% for M/AVR. These current results indicate that the Hancock xenograft valve can be considered as a valid alternative in heart valve replacement.

This article has been cited by other articles:

				N. D. Desai and G. T. Christakis Bioprosthetic Aortic Valve Replacement: Stented Pericardial and Porcine Valves Card. Surg. Adult, January 1, 2008; 3(2008): 857 - 894. [Full Text]

				A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue Eur J Cardiothorac Surg, April 1, 2007; 31(4): 573 - 577. [Abstract] [Full Text] [PDF]

				T. Gherli, A. Colli, C. Fragnito, F. Nicolini, B. Borrello, S. Saccani, R. D'Amico, and C. Beghi Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study Circulation, August 3, 2004; 110(5): 496 - 500. [Abstract] [Full Text] [PDF]

				N. D. Desai and G. T. Christakis Stented Mechanical/Bioprosthetic Aortic Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856. [Full Text]

				H. Bolooki, G. A. Kaiser, S. M. Mallon, G. M. Palatianos, with the technical assistance of, S. Novak, and W. Feuer Comparison of Long-Term Results of Carpentier-Edwards and Hancock Bioprosthetic Valves Ann. Thorac. Surg., November 1, 1986; 42(5): 494 - 499. [Abstract] [PDF]

				F. Nistal, E. Artinano, and I. Gallo Primary Tissue Valve Degeneration in Glutaraldehyde-Preserved Porcine Bioprostheses: Hancock I Versus Carpentier-Edwards at 4- to 7-Years' Follow-up Ann. Thorac. Surg., November 1, 1986; 42(5): 568 - 572. [Abstract] [PDF]